A233 Peptide: A Growth Hormone Secretagogue that Promotes an Antiviral Signaling Pathway

Rebeca Martinez1, Lazaro Gil2, Yassel Ramos3, Luis J Gonzalez3, Mario P Estrada*1 and Vladimir Besada*1

1Animal Biotechnology Division, Center for Genetic Engineering and Biotechnology, Cuba
2Vaccines Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba
3Department of Systems Biology, Center for Genetic Engineering and Biotechnology, Havana, Cuba

Corresponding authors: Vladimir Besada, Department of Systems Biology, Center for Genetic Engineering and Biotechnology; Havana, Cuba, Tel: +53-7271-41-50; Fax: +53-7271-8070; E-mail: vladimir.besada@cigb.edu.cu

Mario P Estrada, Animal Biotechnology Division, Center for Genetic Engineering and Biotechnology, P.O. Box 616, Havana 10600, Cuba, Tel: 5372716022; Fax 53-7271 4764; E-mail: mario.pablo@cigb.edu.cu

Received date: July 12, 2016; Accepted date: August 19, 2016; Published date: August 30, 2016

Copyright: © 2016 Martinez R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Letter to the Editor

Growth hormone secretagogues (GHS) such as ghrelin induce an array of effects in different types of organisms. The role of ghrelin in immune cell activation includes the release of pro- and anti-inflammatory cytokines via different signaling pathways [1,2]. For example, murine RAW 264.7 macrophages express both ghrelin and GHS receptors. Treatment of these cells with exogenous ghrelin decreases LPS-dependent NF-κB activation and subsequent IL-1β and TNF-α production (anti-inflammatory cytokines) while it increases IL10 (anti-inflammatory cytokine) levels through the p38MAPK pathway [3]. GHS also stimulates oxidized LDL uptake by macrophages and PPAR-γ signaling, both being functions associated with the pathogenesis of cardiovascular diseases such as atherosclerosis [4,5].

The A233 decapeptide is a novel synthetic GHS obtained from a massive docking experiment performed against a molecular model of the GHS receptor. Previous studies have demonstrated an impact of peptide treatment on growth, immune system function, and glucose and fatty acid catabolism, the oxidation-reduction process, oxidative damage by showing, for instance, an enhancement of DNA repair and resistance to apoptosis [10]. A233 up-regulates the DNA repair proteins in macrophages, which might promote survival under ROS high level conditions.

The activation of the transcription factors NF-κB, STAT1 and AP-1 by stimuli like LPS, and/or IFN-α/β/γ induces the expression of inflammatory and microbial M1 genes [11,12]. After A233 stimulation J774.2 macrophage cell line shows the up-regulation of Fabp4 protein, a target gene of the STAT1 transcription factor. The expression of Fabp4 in macrophages is induced by a pro-inflammatory environment that promotes NF-κB activation.

It has been shown that patients in every stage of the disease present strong correlations in the levels of DNA methylation at promoters of several NF-kB-related genes [13]. In fact, aberrant DNA methylation patterns have been found in a great number of human disorders, including inflammatory bowel disease, distal colonic neoplasia and even cancers [14-16]. As DNA methyltransferases (DNMTs) are required for the establishment and maintenance of DNA methylation in mammals [17] and some other histone methyltransferases such as G9a and GLP also play a role in the maintenance of DNA methylation [18], A233 might activate macrophage via affect the function of DNMTs or HMTs and alter their associated DNA methylation levels in the immune cells. Nevertheless, this hypothesis should be demonstrated in further experiments.

In vitro studies with A233 peptide have also provoked the secretion of IFN-γ in mouse spleen cells [6]. This cytokine play a crucial role in the antiviral activity against dengue viruses (DENV) [19]. Consequently, a therapeutic treatment of BALB/c mice with this peptide reduced the viral load in a mouse model of DENV intracranial infection. In fact, peptide treatment of J774.2 cells up-regulates the peroxisomal and mitochondrial protein MAVS required for innate immune defense against viruses. The mitochondrial isoform of MAVS activates an IFN-dependent signaling pathway that amplifies and stabilizes the antiviral response through the expression of type I IFNs and other antiviral cytokines [20]. The up-regulation of MAVS, the increase in IFN-γ levels, and the protection against DENV infection indicates an anti-viral effect of A233 peptide treatment, stimulating an innate immune response (Figure 1). Other mouse model studies examining mechanisms of antiviral innate immunity against DENV reveal an essential role for MAVS [21] and IRF-3/7 [22].
Further studies should be conducted to evaluate the use of A233 in biomedical applications. Other growth hormone releasing peptides, that recognized the same cellular receptor (GHSR-1α), have shown to be cardio, neuro and broadly cytoprotective candidates. These molecules have been capable of control cardiac electric potentials and ion pumps and promote cardiomyocytes survival, the attenuation of inflammatory soluble messengers and distal cellular effectors [23]. Additionally they have impacted in the control of peripheral vascular tone, necrosis and apoptosis prevention in a variety of epithelial and non-epithelial structures, the control of sarcopenia by stimulating viral particles.
skeletal muscle trophism, cachexia and catabolism lessening [23]. That is why A233 could have important effects as cyto-protective agent over different tissues. Other important applications, for example in the treatment of autoimmune diseases and in the modulation of immune conditions, should be demonstrated in the appropriated animal models. Also, safety and toxicological studies will be necessary to introduce A233 in the biomedical practices.

Acknowledgment

We thank to MSc. Melyssa Yaugel Novoa (CIGB) for his advice and help in the figure preparation of the manuscript.

References

1. Martínez R, Nunez T, Sanchez A, Ramos Y, Noda J, et al. (2016) A233 Peptide: A Growth Hormone Secretagogue that Promotes an Antiviral Signaling Pathway. J Clin Cell Immunol 7: 450. doi:10.4172/2155-9899.1000450

10. Bauer M, Goldstein M, Christmann M, Becker H, Heylmann D (2011) Human monocytes are severely impaired in base and DNA double-strand break repair that renders them vulnerable to oxidative stress. Proc Natl Acad Sci 108: 21105-21110.

11. Martínez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000 Prime Rep 6: 13.

12. Wang N, Liang H, Zen K (2014) Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol 5: 614.

13. Fernandez-Jimenez N, Castellanos-Rubio A, Plaza-Izurieta L, Izastorza I, Elcoroaristizabal X, et al. (2014) Coregulation and modulation of NFkB-related genes in celiac disease: uncovered aspects of gut mucosal inflammation. Hum Mol Genet 23: 1298-1310.

14. Hartnett L, Egan LJ (2012) Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis 33: 723-731.

15. Hiraoaka S, Kato J, Horii J, Saito S, Harada K, et al. (2011) Methylation status of normal background mucosa is correlated with occurrence and development of neoplasia in the distal colon. Hum Pathol 41: 38-47.

16. Bell A, Bell D, Weber RS, El-Naggar AK (2011) CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. Cancer 117: 2898-2909.

17. Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257.

18. Zhang T, Termanis A, Ozkan B, Bao XX, Culley J, et al. (2016) G9a/GLP Complex Maintains Imprinted DNA Methylation in Embryonic Stem Cells. Cell Rep 15: 77-85.

19. Huang PH, White FM (2008) Phosphoproteomics: unraveling the signaling web. Mol Cell 31: 777-781.

20. Perry ST, Prestwood TR, Lada SM, Benedict CA, Shresta S (2009) Cardif-mediated signaling controls the initial innate response to dengue virus in vivo. J Virol 83: 8276-8281.

21. Chen HW, King K, Tu J, Sanchez M, Luster AD, et al. (2013) The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus. J Immunol 191: 4194-4201.

22. Augustyniak D, Nowak J, Lundy FT (2012) Direct and indirect antimicrobial activities of neuropeptides and their therapeutic potential. Curr Protein Pept Sci 13: 723-738.

23. Berlanga-Acosta J, Guillen G, Lopez-Mola E, Herrera I (2016) Growth hormone releasing peptide-6 (GHRP-6) and other related secretagogue synthetic peptides: A mine of medical potentialities for unmet medical needs. Integrative Molecular Medicine 3: 616-623.